Mucopolysaccharides are more popularly known are long linear, non-repetitious polysaccharide units containing at least one non-lactose sugar with an attached galactose sugar. The repeating two-dimensional sugar unit is composed of amino acid and uric acid, excluding mucopolysaccharides, where in place of the amino acid it contains galactose; the non-galactose sugar, on the other hand, is either glucose or galactose.
Mucopolysaccharides are produced in the intestines through a series of events. First, the ingested food supplies the enzymes required for glycolysis, the process that produces energy from glucose. Glucose is transported to the liver for conversion into glycogen, a material that stores fat and prevents glycolysis from being inhibited. The liver then transports the glycogen back to the small intestine where it is incorporated into long chains of glucose-free glucose and transported back into the bloodstream. These long chains eventually exit the body in the urine.
Research activities upholding stem cell technology application in Mucopolysaccharidosis (MPS) Treatment research in North America, the most promising drugs are the ones that are derived from mucopolysaccharide. These drugs, which are now under phase II of clinical trials, are said to be capable of reducing the activity of Mucopolysaccharides in body cells that generate it, which can lead to preventing or slowing down the growth of certain cancer cells like leukemia and renal cell carcinoma. By using this Mucopolysaccharidosis (MPS) treatment, scientists can hope to find out how this substance affects the ability of cancerous cells to survive.
Read More : https://bit.ly/3gDGMOb
